PEN Penumbra Inc
Surgical & Medical Instruments & Apparatus · NYSE · SEC CIK 1321732 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY17.0%
TTM net income YoY-4.3%
TTM EPS YoY-5.3%
Revenue 3-yr CAGR16.2%
Net income 3-yr CAGR56.9%
Margins
Gross margin68.0%
Operating margin12.1%
Net margin10.1%
FCF margin12.8%
EBITDA margin13.4%
Returns
ROE10.7%
ROA8.3%
ROIC (approx.)12.1%
Asset turnover0.83x
Leverage & solvency
Liabilities / assets21.8%
Debt / equity0.00x
Current ratio5.89x
Interest coverage149.48x
Cash quality & payout
Operating cash flow / net income1.66x
Accruals ratio-5.5%
Payout ratio—
Capex / revenue3.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $410.14M | $390.05M | $374.76M | $385.38M | $354.69M | $339.45M | $324.14M | $315.52M |
| Cost of revenue | $129.84M | $125.10M | $121.35M | $123.26M | $114.27M | $115.44M | $108.26M | $104.80M |
| Gross profit | $280.30M | $264.94M | $253.41M | $262.13M | $240.42M | $224.01M | $215.88M | $210.72M |
| R&D expense | $25.36M | $25.40M | $22.38M | $21.79M | $22.68M | $23.22M | $22.08M | $20.01M |
| SG&A expense | $204.20M | $198.51M | $192.79M | $181.10M | $168.90M | $159.96M | $153.46M | $147.94M |
| Operating income | $50.74M | $41.04M | $38.23M | $59.23M | $48.84M | $40.83M | $40.35M | $42.77M |
| Interest expense | $305,000 | $311,000 | $317,000 | $333,000 | $338,000 | $319,000 | $322,000 | $337,000 |
| Pretax income | $56.32M | $46.19M | $41.69M | $63.63M | $52.33M | $45.31M | $43.86M | $44.34M |
| Income tax | $14.04M | $11.38M | $9.10M | $16.29M | $6.47M | $40,000 | $4.63M | $10.66M |
| Net income | $42.28M | $34.81M | $32.58M | $47.34M | $45.85M | $45.27M | $39.22M | $33.68M |
| EBITDA | $56.20M | $46.65M | $42.81M | $63.69M | $51.33M | $46.34M | $45.37M | $47.16M |
| EPS (basic) | 1.07 | 0.88 | 0.83 | — | 1.17 | 1.17 | 1.02 | — |
| EPS (diluted) | 1.07 | 0.88 | 0.82 | — | 1.17 | 1.15 | 1.00 | — |
| Weighted avg. shares (diluted) | 39.62M | 39.57M | 39.54M | — | 39.30M | 39.25M | 39.16M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $254.28M | $205.27M | $241.29M | $186.90M | $321.03M | $421.77M | $376.05M | $324.40M |
| Short-term investments | $419.33M | $453.52M | $374.37M | $357.92M | $149.27M | $2.79M | $2.79M | $15.73M |
| Receivables | $195.22M | $190.41M | $183.29M | $190.02M | $183.43M | $175.54M | $167.98M | $167.67M |
| Inventory | $459.13M | $442.65M | $438.54M | $431.55M | $432.37M | $427.63M | $415.86M | $406.74M |
| Current assets | $1.38B | $1.34B | $1.28B | $1.22B | $1.14B | $1.07B | $999.71M | $951.12M |
| PP&E, net | $156.44M | $146.72M | $134.06M | $117.44M | $97.73M | $84.83M | $72.47M | $62.64M |
| Goodwill | $166.48M | $166.52M | $166.59M | $166.75M | $166.75M | $166.75M | $166.12M | $165.83M |
| Intangibles | $5.55M | $5.74M | $5.95M | $6.19M | $6.37M | $6.55M | $6.47M | $6.51M |
| Total assets | $2.03B | $1.97B | $1.90B | $1.83B | $1.74B | $1.67B | $1.59B | $1.53B |
| Current liabilities | $233.81M | $233.78M | $211.73M | $183.13M | $169.60M | $157.76M | $158.63M | $158.34M |
| Total liabilities | $441.59M | $443.96M | $424.63M | $398.92M | $385.67M | $380.86M | $380.43M | $382.25M |
| Shareholders' equity | $1.58B | $1.53B | $1.47B | $1.43B | $1.36B | $1.29B | $1.21B | $1.15B |
| Shares outstanding | — | — | — | 39.23M | — | — | — | 38.49M |
| Cash flow statement | ||||||||
| Operating cash flow | $41.51M | $46.08M | $86.97M | $86.48M | $58.26M | $44.95M | $48.97M | $51.11M |
| Capital expenditure | $15.11M | $13.54M | $13.67M | $18.43M | $16.25M | $15.58M | $13.47M | $5.37M |
| Free cash flow | $26.40M | $32.54M | $73.30M | $68.05M | $42.01M | $29.37M | $35.50M | $45.74M |
| Investing cash flow | $8.68M | -$91.09M | -$30.63M | -$225.65M | -$162.86M | -$15.58M | -$502,000 | -$10.96M |
| Financing cash flow | -$1.06M | $9.03M | -$1.91M | $5.06M | $3.95M | $14.82M | $2.71M | $6.07M |
| Depreciation & amortization | $5.47M | $5.62M | $4.57M | $4.46M | $2.49M | $5.51M | $5.01M | $4.39M |
| Stock-based compensation | $14.83M | $13.66M | $14.64M | $15.26M | $15.93M | $14.23M | $13.79M | $12.10M |
| Share buybacks | — | — | — | $0 | — | — | — | -$1,000 |
Free plan shows the latest 8 periods; Pro shows all 51 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.